- $1.82bn
- $1.70bn
- $89.08m
- 69
- 12
- 64
- 46
Annual cashflow statement for RxSight, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | 126 | 27.6 | -48.7 | -66.8 | -48.6 |
| Depreciation | |||||
| Non-Cash Items | -167 | -58.9 | 2.67 | 11.3 | 11.8 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -3.97 | -7.85 | -2.68 | -7.41 | -9.07 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -40.6 | -35.2 | -44.7 | -58.9 | -41.6 |
| Capital Expenditures | -4.09 | -2.54 | -1.94 | -2.39 | -4.81 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -1.78 | 18.1 | -80 | 42.3 | -17.3 |
| Sale of Fixed Assets | |||||
| Change in Net Investments | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -5.87 | 15.6 | -81.9 | 40 | -22.1 |
| Financing Cash Flow Items | 0 | -0.687 | -0.132 | -1.38 | -4.28 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 1.33 | 25.2 | 137 | 6.33 | 61.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -45.2 | 5.63 | 10.7 | -12.6 | -2.19 |